Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OUTSTAND: Neoadjuvant Chemotherapy for Obstructive Colon Cancer
NCT04889820Not yet recruiting
- Sponsor
- The Catholic University of Korea
- Start
- Nov 2021
- Primary completion
- Oct 2027
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
01
Overview
Randomised, open-label trial of oxaliplatin, fluorouracil and folinic acid in colon cancer (2 arms), sponsored by The Catholic University of Korea. Primary endpoint: 3-year overall survival. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
oxaliplatinfluorouracilfolinic acid
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT04889820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04889820.